Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 5Phase 1/2 4Phase NA 2Phase 3 2

Status

Recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Prostatic Neoplasms 8Lung Neoplasms 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Multiple Myeloma 5Melanoma 5Carcinoma, Non-Small-Cell Lung 5Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Glioblastoma 4Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Glioma 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Burkitt Lymphoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Neuroblastoma 2Meningioma 2Lymphoma, B-Cell 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Astrocytoma 2Adenocarcinoma of Lung 2

Interventions

Rituximab 41Cyclophosphamide 23Peripheral Blood Stem Cell Transplantation 15Lenalidomide 14ibrutinib 11fludarabine phosphate 11Etoposide 10Bortezomib 10Filgrastim 9Bendamustine Hydrochloride 9Mycophenolic Acid 8Melphalan 8Cytarabine 8venetoclax 7fludarabine 7Whole-Body Irradiation 7Vincristine 7Cyclosporine 7CT-P10 7Methotrexate 6obinutuzumab 5acalabrutinib 5Doxorubicin 5Carmustine 5Carboplatin 5Biopsy 5pembrolizumab 4ibritumomab tiuxetan 4carmustine, poliferprosan 20 drug combination 4Tacrolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Mantle-Cell × Magnetic Resonance Spectroscopy × Clear all
NCT07578077 2026-05-11

Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Not yet recruiting
58 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT05861050 2026-02-19

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT06357676 2026-01-30

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

OHSU Knight Cancer Institute

Phase 1/2 Recruiting
27 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Fred Hutchinson Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡